Mitral Annulo-TRIpsy in Extreme Risk Patients: 1 Year Outcomes of the MATRIX Procedure
Document Type
Conference Proceeding
Publication Date
6-2026
Publication Title
Structural Heart
Abstract
Background: Severe calcific mitral stenosis (MS) is therapeutically challenging. Intravascular lithotripsy (IVL) can facilitate percutaneous balloon mitral valvuloplasty in patients not amenable to conventional therapies. The Mitral Annulo-TRIpsy in eXtreme risk patients (MATRIX) procedure was feasible, safe with effective reductions in mMG at 30 days in a multicenter series. Methods: The authors report the 1-year outcomes of the MATRIX procedure in patients with severe calcific MS. Results: A total of 12 patients underwent MATRIX procedure. 1-year outcome data was available for 75%, median follow up 295 (49-400) days. Median age 78 years (72-82), 67% female. All presented with progressive NYHA class III-IV symptoms and functional limitations. Pre-MATRIX mean mitral gradient (mMG) 9.0mmHg (7-12.5) and 1-year mMG 7.0mmHg (4-8.5) (absolute difference -3.73; 95% CI: 1.44–6.02; p< 0.01). Absolute difference in mMG 30-days post-MATRIX and 1 year +1.1mmHg (CI: -0.94–3.19, p=0.24). At 1 year all patients were alive without complications of worsening MR, myocardial infarction, stroke, major bleed, pericardial effusion, or reintervention. One patient was re-hospitalized for heart failure exacerbation. Conclusion: This series demonstrates that IVL of MS using MATRIX technique is associated with long-term effective reductions in mMG.
Volume
10
Issue
6 Suppl
First Page
100949
Last Page
100949
Recommended Citation
Asselin C, Naguib M, Jabri A, Kipperman R, Koulogiannis K, Marcoff L, et al. [Abbas A]. Mitral annulo-TRIpsy in extreme risk patients: 1 year outcomes of the MATRIX procedure. Struct Heart. 2026 Jun;10(6 Suppl):100949. doi:10.1016/j.shj.2026.100949
DOI
10.1016/j.shj.2026.100949
Comments
New York Valves The Structural Heart Summit, June 24-26, 2026, New York, NY